According to a new report Global Male Infertility Market, published by KBV research, The Global Male Infertility Market size is expected to reach $3.2 billion by 2026, rising at a market growth of 7.6% CAGR during the forecast period.

Based on treatment, the Assisted Reproductive Technology (ART) and Varicocele Surgery segment dominated the male infertility market in 2019 due to its high success rate. Intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are the most commonly used ARTs. Medications include hormone therapy and corticosteroids, but in only a few cases they are successful.

DNA fragmentation technique emerged as the largest research segment in the industry in 2019 and is expected to retain its lead over the forecast period. Increasing adoption in developing countries and high cost due to higher sensitivity and reliable study of sperm DNA integrity are the main factors driving the market.

North America dominated the regional segment of the male infertility market and held the largest share of total revenue in 2019. This is attributed to the availability of well-equipped and specialized fertility clinics, improved cost-effectiveness of treatment, better diagnosis and medication coverage, and a high level of understanding. The Asia Pacific is projected to see lucrative growth over the forecast period. Emerging countries in the world, including India, China, and Singapore, have experienced rapid economic growth. The Europe market is expected to witness a CAGR of 7.2% during (2020 - 2026).

Structural Insights: https://www.kbvresearch.com/male-infertility-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.

Global Male Infertility Market Segmentation

By Treatment
• Assisted Reproductive Technology & Varicocele Surgery
• Medication

By Tests
• DNA Fragmentation Technique
• Oxidative Stress Analysis
• Computer Assisted Semen Analysis
• Microscopic Examination
• Sperm Agglutination
• Sperm Penetration Assay
• Other Tests

By Geography

North America
• US
• Canada
• Mexico
• Rest of North America

Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled
• Sanofi S.A.
• Bayer AG
• Cadila Healthcare Ltd. (Zydus Cadila)
• Endo International PLC
• Aytu BioScience, Inc.
• Vitrolife AB
• SCSA Diagnostics, Inc.
• Andrology Solutions Limited
• Halotech DNA SL
• Intas Pharmaceutical Ltd.